When Is the Same Database Not the Same? Database Differences Among Systems.

Users of online databases frequently have several options available for searching the same database. Selection of the appropriate access method can be simplified through the evaluation of seven criteria. Price, time periods covered, and frequency and timing of updates should be considered first. Variations in file structure among online systems should also be evaluated. Finally, the online systems themselves should be evaluated for their support systems and search features

Patent Database: Their Importance in Prior Art Documentation and Patent Search

In knowledge based economies the nation’s economic status depends on the production, distribution and use of knowledge and information. The recent trend in the economic growth of nations is mainly determined by innovative technological knowhow of the individuals. Intellectual property has gained attention in this era of knowledge. The vast amount of data generated through the application of intellectual assets is managed with the help of various in- silico tools. In recent days, the patent databases have gained importance due to the detailed information available on the granted patent and other details, such as, legal status of the patent applications, which are not available through any other literature search. This review paper attempts to describe different types of patent databases available, their unique features, strengths, weakness and their major purpose. This paper details the information on how to access a patent database, the relevance of patent information obtained from these databases in prior art search, patent analysis, and the drawbacks present in these patent databases

Bibliometrics, reference enhanced databases and research evaluation

This study presents the panoramic view of the described issues related to coverage, services and bibliometrics for Research Evaluation (RE) purposes by three reference enhanced databases. The researchers’ viewpoint is based on the relevant literature and data accessed from most preferred citation sources: Web of Science, Scopus and Google Scholar.The study seeks the worldview challenges, highlights and theorizes the core issues for those regions and disciplines that have more challenges and fewer opportunities in getting publishing, citing and cited by. It discusses the new insights and directs the stakeholders to explore other possible sources, metrics and evaluation techniques for RE

Special Libraries, November 1980

Volume 71, Issue 11https://scholarworks.sjsu.edu/sla_sl_1980/1009/thumbnail.jp

Special Libraries, Summer 1992

Volume 83, Issue 3https://scholarworks.sjsu.edu/sla_sl_1992/1002/thumbnail.jp

Updating the Crime Reduction Toolkit: A report and manual

The Crime Reduction Toolkit (CRT) is an online repository of narrative summaries of systematic reviews on crime reduction. This report details the methods used to update the CRT, outlining the systematic process and the numbers of records/items dealt with at each stage

Special Libraries, May-June 1977

Volume 68, Issue 5-6https://scholarworks.sjsu.edu/sla_sl_1977/1004/thumbnail.jp

Preliminary Report on Patent Literature, Search Methodology and Patent Status of Medicines on the WHO EML 2009

Over the past several decades the World Health Organization (WHO) has produced the Essential Medicines List (EML) to assist countries in deciding what medicines should be essential and available in National Essential Medicine Lists.1 WHO, through the work of regional offices, supports nations using the EML to ensure the quality, availability, and affordability of pharmaceuticals required to promote and advance public health in nations across the globe. However in some cases, access to EML pharmaceuticals might be complicated by existing patents, i.e., where issued, patent rights might pose obstacles to access and inclusion in national EMLs. Indeed, in developed and emerging economy national jurisdictions patent protection may be in effect for a not insignificant number of the WHO EML pharmaceuticals (Figure 2A). However, in developing countries, it is uncertain whether these patents have been filed or issued. Without patent data predicated on an established, reproducible protocol for accessing and assembling patent information on the EML pharmaceuticals, discussions, debates and strategic approaches to understanding and managing patents with regard to access and delivery to developing countries remain in the dark. Indeed, it is absurd to make policy and formulate strategy without solid patent information: the critical foundation for rational debate. To analyze the degree and scope of patenting of EML pharmaceuticals, WIPO (with WHO) approached the Franklin Pierce Center for Intellectual Property at the University of New Hampshire School of Law, specifically the International Technology Transfer Institute (ITTI) to generate a preliminary overview of patents appurtenant to recently added pharmaceutical updates to the EML.2 As part of this work, with inputs from WHO and WIPO, ITTI developed novel methodology and a detailed protocol for identifying EML pharmaceutical patents in national jurisdictions, with an easily reproducible yet cost effective template. Herein is described the development of such a protocol and a preliminary pool of patent information that illustrates its utility. The protocol yields data in a layered approach thereby allowing a user to quickly and effectively obtain both broad and detailed patent information for medications on the WHO EML. In addition, the protocol can be used as an initial path for targeted strategic analysis of potentially relevant patent information in national jurisdictions. In sum, the objectives for this project were: To develop a robust methodology to assess the patent status of medicines on the WHO Model List of Essential Medicines; To place in the public domain a detailed report on the present (2010) patent status of medicines that were on patent in 2003 and those medicines added to the Model List since 2003 by country and level of development; and To analyze the patent status of these Essential Medicines by the development status of countries. The report describes the development of the protocol and presents a preliminary list of EML and corresponding patents in certain jurisdictions to illustrate the utility of the approach. Results will be discussed both in terms of global access and patents, and in the context of establishing standard, systematic, protocols for periodic patent searches related to EML content. 1 WORLD HEALTH ORGANIZATION, CONTINUITY AND CHANGE IMPLEMENTING THE THIRD WHO MEDICINES STRATEGY 2008--‐2013 20 (WHO Press, 3rd ed. 2009). 2 This report covers the EML up to and including updates until 2009